News from cardio3 biosciences A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 02, 2015, 11:48 ET Cardio3 BioSciences marks first important milestone in regulatory path toward C-Cure® market registration with Paediatric Investigation Plan waiver from EMA

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of specialized cell therapies, today...


Jan 26, 2015, 12:36 ET Cardio3 BioSciences Announces Agenda And Webcast For 2015 NYC Investor Day

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, today announces agenda...


Jan 13, 2015, 02:34 ET Cardio3 BioSciences to Host Investor & Analyst Day in New York on Friday, January 30, 2015

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, will host an Investor &...


Dec 19, 2014, 10:03 ET Cardio3 Biosciences Announces the Enrolment of the 240th Patient for its CHART-1 Phase III Clinical Trial for the Treatment of Heart Failure

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...


Dec 17, 2014, 03:00 ET Cardio3 Biosciences Will be Present at ODDO Midcap Forum

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the development of regenerative therapies, announces its participation in ...


Dec 15, 2014, 09:00 ET Cardio3 Biosciences to Address American Institutional Investors in January at J.P. Morgan Healthcare Conference

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the development of regenerative therapies, announces its participation in ...


Nov 26, 2014, 04:00 ET Cardio3 BioSciences Announces the Nomination of Three Co-principal Investigators for its CHART-2 Phase III Clinical Trial of C-Cure® for the Treatment of Heart Failure

Dr Bernard J. Gersh, Dr Thomas Povsic and Dr Gerasimos Filippatos will be Co-Principal Investigators of the phase III clinical trial CHART-2,...


Nov 18, 2014, 11:45 ET Cardio3 BioSciences Announces Q3 2014 Business Update

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...


Nov 05, 2014, 12:01 ET Cardio3 BioSciences Acquires CorQuest Medical Inc.

Cardio3 BioSciences acquires CorQuest Medical Inc. and its unique heart access platform that could receive CE marking by end 2016 Acquisition...


Oct 23, 2014, 02:00 ET Cardio3 Biosciences Appoints Dr. Warren Sherman as Chief Medical Officer

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...


Oct 13, 2014, 11:45 ET Cardio3 Biosciences Receives Authorization to Enroll Patients in Switzerland in its Phase III Clinical Trial Chart-1

CHART-1 trial represents the world's first Phase III trial in regenerative medicine for a pre-programmed cellular therapy targeting heart failure To...


Feb 24, 2014, 08:24 ET Cardio3 BioSciences Strengthens IP Portfolio with New US Patent

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...


Jan 09, 2014, 09:00 ET Cardio3 BioSciences Receives IND Clearance from the FDA for its CHART-2 Phase III Heart Failure Clinical Trial

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...


Dec 30, 2013, 06:30 ET Cardio3 BioSciences Announces Participation at the 32nd Annual JP Morgan Healthcare Conference in San Francisco

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...


Dec 16, 2013, 01:27 ET Cardio3 BioSciences Raises € 4.0 Million in Non-dilutive Funding from the Walloon Region

The biotechnology company, Cardio3 BioSciences SA ('Cardio3' or 'the Company'), a leader in the discovery and development of regenerative, protective ...


Dec 11, 2013, 12:00 ET Cardio3 BioSciences C-Cath® Article Published in Circulation Cardiovascular Interventions

Study Demonstrates Enhanced Endomyocardial Therapeutics Retention through an Optimized Delivery System Cardio3 BioSciences (C3BS) (NYSE Euronext...


Dec 03, 2013, 11:35 ET Cardio3 BioSciences Partner and Exploitation Manager of a Eur 6.8 Million FP7 Research Grant for AMCARE Program

Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...


Nov 25, 2013, 05:49 ET Cardio3 BioSciences Partner and Exploitation Manager of a Eur 4.5 Million FP7 Research Grant

Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...


Nov 21, 2013, 03:00 ET Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Wallonia

The Belgian biotechnology company Cardio3 BioSciences (C3BS)(NYSE Euronext Brussels and Paris : CARD), leader in the discovery and development of...


Nov 12, 2013, 12:26 ET Cardio3 BioSciences Announces Q3 2013 Business Update and Authorization to Enroll Patients in Poland in its Chart-1 Phase III Clinical Trial

Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...


Oct 23, 2013, 05:56 ET Cardio3 BioSciences Receives Authorization to Enroll Patients in Italy in its Phase III Clinical Trial CHART-1

CHART-1 trial represents the world's first Phase III trial in regenerative medicine for a pre-programmed cellular therapy targeting heart failure To...


Oct 14, 2013, 01:30 ET Cardio3 BioSciences to Participate at the KBC Securities Benelux Biotech Healthcare Conference in New York on November 13 & 14

The Belgian biotechnology company Cardio3 BioSciences (C3BS), leader in the discovery and development of regenerative, protective and reconstructive...


Oct 07, 2013, 02:30 ET Cardio3 BioSciences Strengthens Management Team by Appointing Dr. Gaëtane Metz as Chief Operating Officer

The Belgian biotechnology company Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative, protective and...


May 08, 2013, 06:19 ET Cardio3 BioSciences Raises €19 Million Through a Private Placement

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative, protective and...


Apr 11, 2013, 04:00 ET Results from Cardio3BioSciences C-CURE® Trial Published in the Journal of the American College of Cardiology

Trial Demonstrates Statistically Significant Improvements in Heart Function and Exercise Tolerance with Cardiopoietic Stem Cell Therapy Cardio3...